RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2014.
“Our Company achieved a major milestone in the second quarter with the launch of our Phase 3 study of Pyridorin in diabetic nephropathy,” said Chief Executive Officer Pierre Legault. “Along with the clinicians involved in the trial, we are excited to have begun this work because there are no adequate treatments for the estimated 6 million people in the U.S. alone who suffer from this chronic, life-threatening disease. NephroGenex is well positioned to advance this critical program with a Special Protocol Assessment (SPA) from the FDA for a unique, fully approvable endpoint that is expected to significantly reduce the time and cost of the trial.”
Help employers find you! Check out all the jobs and post your resume.
